Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method
暂无分享,去创建一个
[1] A. Kadi,et al. Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes , 2023, Molecules.
[2] A. Kadi,et al. Development of an LC-MS/MS Method for Quantification of Sapitinib in Human Liver Microsomes: In Silico and In Vitro Metabolic Stability Evaluation , 2023, Molecules.
[3] A. Kadi,et al. A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes , 2022, RSC advances.
[4] M. Gaze,et al. Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma. , 2021, European journal of cancer.
[5] Kun Wang,et al. Determination of selpercatinib, a RET kinase inhibitor, in rat plasma and its application to a pharmacokinetic study. , 2020, Biomedical chromatography : BMC.
[6] Jiang Liu,et al. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions , 2020, Clinical Cancer Research.
[7] J. Beijnen,et al. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. , 2020, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[8] G. Rossi,et al. Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. , 2020, Critical reviews in oncology/hematology.
[9] G. Lippi,et al. Current Cancer Epidemiology , 2019, Journal of epidemiology and global health.
[10] V. Adamo,et al. RET fusions in solid tumors. , 2019, Cancer treatment reviews.
[11] A. Gunia-Krzyżak,et al. Metabolic stability and its role in the discovery of new chemical entities , 2019, Acta pharmaceutica.
[12] A. Kadi,et al. Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability , 2019, PloS one.
[13] A. Kadi,et al. A simple liquid chromatography-tandem mass spectrometry method to accurately determine the novel third-generation EGFR-TKI naquotinib with its applicability to metabolic stability assessment , 2019, RSC advances.
[14] Jonathan D. Tyzack,et al. Computational methods and tools to predict cytochrome P450 metabolism for drug discovery , 2019, Chemical biology & drug design.
[15] A. Kadi,et al. Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC–MS/MS: in vitro metabolic investigation , 2019, Royal Society Open Science.
[16] A. Drilon,et al. A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. , 2018 .
[17] Jonathan D. Tyzack,et al. WhichP450: a multi-class categorical model to predict the major metabolising CYP450 isoform for a compound , 2018, Journal of Computer-Aided Molecular Design.
[18] A. Kadi,et al. LC–MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate , 2017, Chemistry Central Journal.
[19] Johannes Kirchmair,et al. Drug Metabolism Prediction , 2014 .
[20] Hoa Le,et al. Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop. , 2011, Combinatorial chemistry & high throughput screening.
[21] James V Belcastro,et al. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. , 2008, Assay and drug development technologies.
[22] D. Leahy,et al. Integrating invitro ADMET data through generic physiologically based pharmacokinetic models , 2006, Expert opinion on drug metabolism & toxicology.
[23] J. Brockmöller,et al. Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. , 2000, British journal of clinical pharmacology.
[24] W. Busby,et al. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[25] M. Barinaga. From Bench Top to Bedside , 1997, Science.
[26] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[27] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[28] D. Pessayre,et al. Inactivation of cytochrome P-450 by the drug methoxsalen. , 1986, The Journal of pharmacology and experimental therapeutics.